Syngene Delivers ₹867 Million Profit In Q1 FY26 On Steady Operational Growth

Syngene International Ltd has reported a consolidated net profit of ₹867 million for the quarter ended June 2025, supported by consistent demand across its contract research and manufacturing services. Revenue from operations stood at ₹8.75 billion, reflecting a stable year-on-year performance amid global headwinds.

 

Key Highlights From The Quarterly Results

 

- Revenue grew 5.4 percent year-on-year, driven by strong traction in discovery and development services.

- Net profit of ₹867 million marks a sequential improvement from ₹757 million in Q1 FY25, aided by cost discipline and favorable currency movement.

- EBITDA margins remained healthy at 23.6 percent, supported by operational efficiencies and optimized resource allocation.

- The company maintained a robust order book, with continued client additions across North America and Europe.

 

Strategic Developments And Expansion

 

- Syngene commissioned a new biologics manufacturing facility in Bengaluru, enhancing its capacity for clinical and commercial supply.

- Investments in AI-driven drug discovery and automation tools are expected to improve turnaround times and scalability.

- The company reaffirmed its FY26 guidance, targeting double-digit revenue growth and margin expansion through portfolio diversification.

 

Outlook

 

With a diversified client base and expanding capabilities, Syngene remains well-positioned to capitalize on global outsourcing trends in life sciences. Its Q1 performance underscores resilience and strategic clarity in a competitive CRO/CDMO landscape.

 

Sources: Economic Times, Moneycontrol, Syngene International Filings, Business Standard.